Tivic Health Systems, Inc. issued a press release reporting full year 2025 financial results, including operating expenses of $7.9 million and loss from discontinued operations of $900,000, with net loss expected at $8.8 million to $9.1 million. The company announced its strategic transformation into an immunotherapy company, acquiring Entolimod rights and establishing Velocity Bioworks CDMO.
Key takeaways
Operating expenses $7.9 million for year ended December 31, 2025 vs $4.5 million in 2024
Loss from discontinued operations $900,000 for 2025, decreased by $300,000 from 2024
Net loss expected $8.8 million to $9.1 million for 2025 vs $5.7 million in 2024
Cash and equivalents $12.6 million as of December 31, 2025 vs $2.0 million at December 31, 2024
Acquired exclusive global rights to Entolimod for acute radiation syndrome from Statera Biopharma, Inc.
Appointed Michael K. Handley as CEO in March 2026 succeeding Jennifer Ernst
Issued $16.3 million Senior Secured Convertible Note Payable dated December 10, 2025 to acquire Velocity Bioworks assets